Skip to main content
Contact Us
Subscribe
E-Edition
80°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Pyxis Oncology
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
April 02, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
March 25, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 18, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
March 03, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
February 26, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
February 04, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
December 19, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
November 20, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
November 12, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
November 11, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
August 29, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
August 14, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
July 29, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 28, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
June 10, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
SNDX
Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
May 30, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
May 14, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
May 09, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 28, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
March 27, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
March 21, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
March 13, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
March 07, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
March 05, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Announces $50 Million Private Placement
February 27, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 29, 2023
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
November 28, 2023
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
November 07, 2023
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023
September 27, 2023
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology to Participate in Two Upcoming Investment Conferences
August 31, 2023
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.